Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Calvo

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Communications Biology|June 11, 2021
Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cellsLaetitia Seguin, Soline Odouard, Francesca Corlazzoli, et al.
Digestive Diseases and Sciences|December 21, 2016
Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose EscalationCarlos Taxonera, Eva Iglesias, Fernando Muñoz, et al.
Gastroenterologia Y Hepatologia|June 15, 2021
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE StudyJuan Turnes, Diego Rincón, José L Calleja, et al.
Gastroenterologia Y Hepatologia|December 13, 2024
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel DiseaseMariam Aguas Peris, Javier Del Hoyo Francisco, Pilar Nos Mateu, et al.
Scientific Reports|October 21, 2020
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patientsMarisa Iborra, Natalia García-Morales, Saoia Rubio, et al.
Frontiers in Immunology|October 9, 2025
Correction: Recurrent reproductive failure and celiac genetic susceptibility, a leading role of glutenEduardo de la Fuente-Munoz, Miguel Fernández-Arquero, Nabil Subhi-Issa, et al.
Inflammatory Bowel Diseases|July 4, 2017
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative ColitisCarlos Taxonera, Cristina Rodríguez, Federico Bertoletti, et al.
Frontiers in Immunology|November 8, 2024
Recurrent reproductive failure and celiac genetic susceptibility, a leading role of glutenEduardo de la Fuente-Munoz, Miguel Fernández-Arquero, Nabil Subbhi-Issa, et al.
Digestive Diseases and Sciences|June 6, 2015
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative ColitisCarlos Taxonera, Manuel Barreiro-de Acosta, Marta Calvo, et al.
Medwave|June 26, 2025
Descriptive analysis of immunological abnormalities in recurrent reproductive failure and therapeutical outcomesEduardo de la Fuente-Muñoz, Nabil Subhi-Issa, Ángela Villegas Mendiola, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Communications Biology|June 11, 2021
Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cellsLaetitia Seguin, Soline Odouard, Francesca Corlazzoli, et al.
Digestive Diseases and Sciences|December 21, 2016
Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose EscalationCarlos Taxonera, Eva Iglesias, Fernando Muñoz, et al.
Gastroenterologia Y Hepatologia|June 15, 2021
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE StudyJuan Turnes, Diego Rincón, José L Calleja, et al.
Gastroenterologia Y Hepatologia|December 13, 2024
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel DiseaseMariam Aguas Peris, Javier Del Hoyo Francisco, Pilar Nos Mateu, et al.
Scientific Reports|October 21, 2020
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patientsMarisa Iborra, Natalia García-Morales, Saoia Rubio, et al.
Frontiers in Immunology|October 9, 2025
Correction: Recurrent reproductive failure and celiac genetic susceptibility, a leading role of glutenEduardo de la Fuente-Munoz, Miguel Fernández-Arquero, Nabil Subhi-Issa, et al.
Inflammatory Bowel Diseases|July 4, 2017
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative ColitisCarlos Taxonera, Cristina Rodríguez, Federico Bertoletti, et al.
Frontiers in Immunology|November 8, 2024
Recurrent reproductive failure and celiac genetic susceptibility, a leading role of glutenEduardo de la Fuente-Munoz, Miguel Fernández-Arquero, Nabil Subbhi-Issa, et al.
Digestive Diseases and Sciences|June 6, 2015
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative ColitisCarlos Taxonera, Manuel Barreiro-de Acosta, Marta Calvo, et al.
Medwave|June 26, 2025
Descriptive analysis of immunological abnormalities in recurrent reproductive failure and therapeutical outcomesEduardo de la Fuente-Muñoz, Nabil Subhi-Issa, Ángela Villegas Mendiola, et al.
Pageof 13